Laziros (Azacitidine)

Azacitidine is incorporated into RNA and DNA during cell replication. In DNA, it inhibits DNA methyltransferase, leading to hypomethylation and re‑activation of tumor suppressor genes. In RNA, it disrupts protein synthesis, together causing cytotoxic effects on abnormal hematopoietic cells.

The specific dose and schedule of Laziros are determined by the prescribing physician based on the patient’s condition, disease severity, and clinical response. Dosage may be adjusted according to blood count monitoring and tolerance.

Safety data for azacitidine in pregnancy and lactation are limited. It should only be used if the potential benefits justify the potential risks to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To order Laziros, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Azacitidine belongs to the DNA methyltransferase inhibitor class, offering a distinct mechanism compared with conventional chemotherapy. It is often preferred for patients who may not tolerate intensive regimens, providing disease‑modifying benefits and a different safety profile.

Laziros should be stored refrigerated at 2‑8 °C. Keep the product in its original container, protect it from light, and avoid freezing or shaking the solution to maintain stability and potency.

Laziros is given as a subcutaneous injection, typically by a healthcare professional. The injection site is rotated to reduce local irritation, and the administration schedule is set by the treating physician.

The most serious risks include severe cytopenias (low blood counts), infections, tumor lysis syndrome, and rare but severe allergic reactions. Patients should be monitored closely for signs of infection, bleeding, or sudden metabolic changes.

Laziros is contraindicated in patients with known hypersensitivity to azacitidine or any of its excipients. It should also be avoided in individuals with uncontrolled infections or severe organ dysfunction unless the treating physician determines that the benefits outweigh the risks.